Revenue rose 8% year-on-year to EUR 3.4 million, driven by Lifecare growth and strong SaaS margins. Adjusted EBITDA margin held at 34% despite U.S. expansion investments, and operating cash flow remained positive for the seventh consecutive quarter. RTM launch, share buyback, and NHS contracts were key milestones.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.